Ajanta Pharma reported strong FY26 results with consolidated revenue at ₹ 5,453 crore and PAT at ₹ 1,056 crore. Growth was driven by its US generics and India business, despite challenges in Asia.

Ajanta Pharma Posts Strong FY26 Results

Consolidated Revenue: ₹ 5,453 crore
Consolidated PAT: ₹ 1,056 crore

Reader Takeaway: Robust growth in US generics and India offsets Asia's drag; currency losses are a watch point.

What just happened

Ajanta Pharma has announced its financial results for the fiscal year 2026, reporting a consolidated revenue of ₹ 5,453 crore, a 17% increase from ₹ 4,648 crore in FY 2025. The company's Profit After Tax (PAT) grew by 15% to ₹ 1,056 crore from ₹ 920 crore in the previous year. Adjusted EBITDA saw an 18% rise to ₹ 1,498 crore.

Why this matters

The strong performance indicates Ajanta Pharma's ability to grow its top and bottom lines effectively. Key growth drivers included a significant 49% surge in US generics and a 14% expansion in the India business, outperforming the market. This resilience is crucial for investor confidence.

The backstory

Ajanta Pharma's strategy revolves around its Branded Generics segment, which accounts for 68% of its revenue, with significant presence in India, Asia, and Africa. The company has been actively launching new products and investing in research and development.

What changes now

The company plans to build on this performance in FY 2027. Investments in manufacturing capacity at its Pithampur facility and R&D infrastructure are expected to support future growth. Ajanta Pharma is focused on driving growth in its key markets and product segments.

Risks to watch

Ajanta Pharma faced currency volatility, with a ₹ 103 crore mark-to-market hedge loss due to INR depreciation. Additionally, geopolitical challenges in the Middle East impacted its Asia business, causing a 1% decline. These factors could influence future profitability.

Peer comparison

While specific peer comparisons are not detailed in the filing, Ajanta Pharma's India business grew 14%, outperforming the Indian Pharmaceutical Market (IPM) by 300 basis points. This suggests a competitive edge in its domestic operations.

Context metrics (time-bound)

• FY26 Revenue: ₹ 5,453 crore (vs ₹ 4,648 crore in FY25)
• FY26 PAT: ₹ 1,056 crore (vs ₹ 920 crore in FY25)
• US Generics Growth: 49%
• India Business Growth: 14%
• Asia Business Growth: -1%
• R&D Investment: ₹ 252 crore (5% of revenue)
• Capital Expenditure: ₹ 330 crore

What to track next

Investors will be keen to see Ajanta Pharma's progress in regaining growth momentum in the Asia market. Monitoring the success of new product launches, R&D pipeline, and the impact of currency fluctuations will be key.